Company Overview
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -785.6%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -785.56% |
Stock Price Performance
| 1 Year: | -96.23% |
| 6 Months: | +85.88% |
| 3 Months: | +31.67% |
| 1 Month: | +36.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)70.95 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBM Psyence Biomedical Ltd. PHARMA | 4.74 | -0.38 | $18.08M | 0.00% | -35.09% | -58.62% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | - |
| Gross Profit | - |
| Operating Expenses | 1.51M |
| Operating Income | -1.51M |
| EBITDA | -749.17K |
| Interest Expense | 2.75K |
| Pretax Income | -753.25K |
| Tax Provision | - |
| Net Income | -753.25K |
| Diluted EPS | -3.19 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 3.23M | 43.35M | 3.66M | 5.95M |
| Operating Income | - | -3.23M | -43.35M | -3.66M | -5.95M |
| EBITDA | - | -3.21M | -51.11M | 1.03M | -6.92M |
| Interest Expense | - | 0 | 52.94K | 9.27K | 9.52K |
| Pretax Income | - | -3.21M | -51.16M | 1.01M | -6.94M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -3.21M | -51.16M | 1.01M | -6.94M |
| Diluted EPS | -544.78 | -940.02 | -14,274.29 | 32.76 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1.59M | 1.13M | 7.32M | 17.57M |
| Current Assets | - | 1.59M | 1.13M | 6.56M | 9.11M |
| Cash & Equivalents | - | 1.33M | 733.19K | 6.14M | 7.44M |
| Inventory | - | - | - | - | - |
| Receivables | - | 149.37K | 41.75K | 137.35K | 362.76K |
| Total Liabilities | - | 1.79M | 12.10M | 594.37K | 623.19K |
| Current Liabilities | - | 1.79M | 12.10M | 594.37K | 623.19K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 10.45M | - | - |
| Total Equity | - | -200.44K | -10.97M | 6.72M | 16.94M |
| Shares Outstanding | - | 3.41K | 3.58K | 90.88K | 2.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.59M | -2.95M | -3.73M | -8.14M |
| Investing Cash Flow | - | 0 | -5.73K | -16.23K | -4.51M |
| Financing Cash Flow | - | 1.17M | 2.35M | 9.15M | 13.96M |
| Capital Expenditure | - | - | -5.73K | -9.88K | -500.23K |
| Free Cash Flow | - | -1.59M | -2.95M | -3.74M | -8.64M |
| Net Change in Cash | - | -419.16K | -601.09K | 5.40M | 1.31M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 1,599.6% | 466.2% | 15.1% | -40.9% |
| ROCE % | - | 1,613.8% | 395.1% | -54.5% | -35.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Parallel Advisors, LLC | 3.97% | 151.25K | $1.00M |
| 2 | AdvisorShares Investments, LLC | 3.20% | 122.18K | $809.47K |
| 3 | Morgan Stanley | 0.99% | 37.80K | $250.45K |
| 4 | Jane Street Group, LLC | 0.80% | 30.43K | $201.60K |
| 5 | Xtx Topco Ltd | 0.40% | 15.09K | $100.00K |
| 6 | Citadel Advisors Llc | 0.31% | 11.69K | $77.47K |
| 7 | UBS Group AG | - | 60 | $397 |
| 8 | Caitlin John, LLC | - | 35 | $231 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBM
PSYENCE BIOMEDICAL LTD. SEC Filing (Sep 2, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOeWFSQ0RENHJpbWFzVFRBNURLRjczVl9RVGFfX3NlSG1Ra3JuYW42dDIxckNVUkI5aXV0SHE1SVZWNE1QYUt4T3ZnT3oxOWF5N2hBLVJEQV92cUNUd3BpZFFTbEhxTlp6U2tHTnRsUWJpcHdGc1FCSGk4UF9USi1XVDVWbHJFNDcwRU9JZD…
Why Is PBM Stock More Than Doubling Premarket Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNNjU3R2s0d1BETEpDLVNhRUo5eEVXYURpRElUa0xVQkN6SkFxaHkyQ0lLcGx3UFBFLWl2Z3JiRl9LNkRwNk1nVncxT3NZNllDak5HOU93YW0xeUpiRWVXalk5UERXc2NDZERkZ3I5RlVDc0U2ZV9QT09rTFVyNS1HY0lfZW10QnNhUEtKNV…
Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE93ckV0b1B3LU1GMjB5Y3lQZ0dZNFFLVk9LR3FJR2pfcFZab3ZYQUhHaDRKUFhCOVl1UU1RT3pnX1N4bGUzZnlxTE1qNjVUWE8yXzF1Ug?oc=5" target="_blank">Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM) S…
Modular Medical Shares Climb as Pivot Pump Gains National PBM Coverage - finance.biggo.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1mRjJxbUVva2JkNWtFMndGRUZwVlh6M1E5M0ZCZWcwamduTTlLLUVmVnhnTWdSUzJMdkNnQ0NYR1lUampJbktzc2N4QXZveUx6eXN0YTUwbzREcjZReUhFbzN2Qk96SlV0UnpuYnpyandkOUxRdGc?oc=5" target="_blank">Modular …
Psyence Biomedical (PBM) soars 203.8% as micro-cap momentum builds around recent clinical-trial updates and corporate actions | PBM Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPYVJSbVFZeUNQN0M5ZF9Sa1Q4enNWOVBIelBCODNVVkR2QWstWVNQaXNCYmFxWTkwc3QyR1NoQTMzaGdVNllBZzhWR1U5YWpWcUlJd2JYSXFjNFBlM2J5S3k4QXlVcDZXSFBDSmZYQWd2bkQxTnJJMV9CSVhZUzlYZDh6UENYeDlyYldvRW…
PBM - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE5HNVE0OEp6bFJwT2tCdTFpZC1LOFlzTnBVMG5LZnlOam1zSXhCb2NqN1N4enh3NDhUTG5XRVpjQmEzMXJG?oc=5" target="_blank">PBM</a> <font color="#6f6f6f">Finviz</font>…
PBM — Frequently Asked Questions
What is the current share price of Psyence Biomedical Ltd. (PBM)?
As of 2026-09-19 21:16 PDT, Psyence Biomedical Ltd. (PBM) trades at $4.74 on NasdaqCM. Its 52-week range is $2.23 to $207.03.
What is the market capitalisation of PBM?
Psyence Biomedical Ltd. (PBM) has a market capitalisation of $18.08M on NasdaqCM.
What is the P/E ratio of PBM?
PBM trades at a trailing price-to-earnings (P/E) ratio of -0.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.90.
What is the return on equity (ROE) of PBM?
PBM has a return on equity (ROE) of -58.62%. Its return on capital employed (ROCE) is -35.09%.
Is PBM a good stock to buy?
This page provides a data-driven analysis of Psyence Biomedical Ltd. (PBM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.